Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms

O B Goreva; A Yu Grishanova; O V Mukhin; N P Domnikova; V V Lyakhovich

doi:10.1023/a:1026331326648

Possible prediction of the efficiency of chemotherapy in patients with lymphoproliferative diseases based on MDR1 gene G2677T and C3435T polymorphisms

Bull Exp Biol Med. 2003 Aug;136(2):183-5. doi: 10.1023/a:1026331326648.

Authors

O B Goreva¹, A Yu Grishanova, O V Mukhin, N P Domnikova, V V Lyakhovich

Affiliation

¹ Institute of Molecular Biology and biophysics, Siberian Division of Russian Academy of Medical Sciences, Novosibirsk. gob@ngs.ru

PMID: 14631505
DOI: 10.1023/a:1026331326648

Abstract

Study of polymorphism in MDR1 gene exons 21 and 26 revealed that T2677T and T3435T alleles are not a factor predisposing to lymphoproliferative diseases, but they determine the efficiency chemotherapy. Individuals with T2677T and T3435T haplotypes are at highest risk of drug resistance. Association between genotypes G2677T and C3435T was detected in normal subjects and in patients with lymphoproliferative diseases.

Publication types

Research Support, Non-U.S. Gov't

MeSH terms

Alleles
Antineoplastic Agents / therapeutic use*
Genes, MDR*
Genotype
Humans
Leukemia, Lymphoid / drug therapy*
Leukemia, Lymphoid / genetics
Lymphoma, Non-Hodgkin / drug therapy*
Lymphoma, Non-Hodgkin / genetics
Polymerase Chain Reaction
Polymorphism, Genetic*
Predictive Value of Tests

Substances

Antineoplastic Agents